Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05035654
Registration number
NCT05035654
Ethics application status
Date submitted
27/08/2021
Date registered
5/09/2021
Date last updated
21/09/2023
Titles & IDs
Public title
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
Query!
Scientific title
BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy
Query!
Secondary ID [1]
0
0
LYR-220-2021-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Sinusitis
0
0
Query!
Chronic Rhinosinusitis (Diagnosis)
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - LYR-220 Design 1
Treatment: Drugs - LYR-220 Design 2
Treatment: Drugs - Bilateral sham procedure control
Experimental: Treatment Arm A: LYR-220 Design 1 - Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
Experimental: Treatment Arm B: LYR-220 Design 2 - Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Sham Comparator: Treatment Arm C: Bilateral sham procedure control - Bilateral sham procedure control
Treatment: Drugs: LYR-220 Design 1
LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
Treatment: Drugs: LYR-220 Design 2
LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Treatment: Drugs: Bilateral sham procedure control
Bilateral sham procedure control
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Product-related unexpected serious adverse events
Query!
Assessment method [1]
0
0
Product-related unexpected serious adverse events
Query!
Timepoint [1]
0
0
Through Week 28
Query!
Primary outcome [2]
0
0
Plasma MF concentrations
Query!
Assessment method [2]
0
0
Plasma MF concentrations
Query!
Timepoint [2]
0
0
Through Week 25
Query!
Secondary outcome [1]
0
0
Adverse Events
Query!
Assessment method [1]
0
0
Severity and percentage of subjects reporting treatment-emergent adverse events and serious adverse events
Query!
Timepoint [1]
0
0
Through Week 28
Query!
Secondary outcome [2]
0
0
Laboratory Values (hematology and chemistry)
Query!
Assessment method [2]
0
0
Percentage of subjects with abnormal and clinically significant abnormal laboratory values
Query!
Timepoint [2]
0
0
Through Week 25
Query!
Secondary outcome [3]
0
0
Endoscopic findings
Query!
Assessment method [3]
0
0
Percentage of subjects with newly identified or worsened endoscopic findings in the ethmoid cavity (mild, moderate, or severe)
Query!
Timepoint [3]
0
0
Through Week 25
Query!
Secondary outcome [4]
0
0
Ophthalmic Assessment: Intraocular Pressure (IOP)
Query!
Assessment method [4]
0
0
Percentage of subjects with clinically significant increase in IOP
Query!
Timepoint [4]
0
0
Through Week 25
Query!
Secondary outcome [5]
0
0
Ophthalmic Assessment: Cataract
Query!
Assessment method [5]
0
0
Percentage of subjects with newly identified or worsened cataract in one or both eyes
Query!
Timepoint [5]
0
0
Through Week 25
Query!
Secondary outcome [6]
0
0
Improving Chronic Rhinosinusitis (CRS) specific Quality of Life as per the 22-item sino-nasal outcome test (SNOT-22) questionnaire
Query!
Assessment method [6]
0
0
Change from baseline in total patient-reported outcome measures. Each symptom is scored as it has been over the past two weeks on a 6-point scale (0 to 5: 0 = no problem to 5 = problem as bad as it can be). Higher scores indicate severity of symptoms.
Query!
Timepoint [6]
0
0
Through Week 28
Query!
Secondary outcome [7]
0
0
Change in Chronic Rhinosinusitis (CRS) symptom scores
Query!
Assessment method [7]
0
0
Change from baseline in the average composite score
Query!
Timepoint [7]
0
0
Through Week 28
Query!
Eligibility
Key inclusion criteria
- Diagnosis of chronic rhinosinusitis.
- Has had a prior bilateral total ethmoidectomy.
- Has computed tomography (CT) ethmoid cavity opacification.
- Has a Sinonasal Outcome Test (SNOT-22) = 20 at Screening Visit.
- Minimum cardinal symptom score.
- Has been informed of the nature of the study and has provided written informed consent
as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the
respective clinical site or regulatory authority if applicable by national law.
- Agrees to comply with all study requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pregnant or breast feeding.
- Known history of hypersensitivity or intolerance to corticosteroids.
- History or clinical evidence or suspicion of invasive fungal sinusitis, allergic
fungal rhinosinusitis, or atrophic rhinitis.
- Known history of hypothalamic pituitary adrenal axial dysfunction.
- Had dental procedure/implant on maxillary dentition within 4 weeks of the Screening
visit.
- Past or present functional vision in only one eye.
- Past, present, or planned organ transplant or chemotherapy with immunosuppression.
- With prior cataract surgery or presence (in either eye) of posterior subcapsular
cataract of grade 2 or higher, nuclear cataract of grade 3 or higher, or cortical
cataract of grade 2 or higher or involving a minimum of center optic zone of 3 mm
diameter.
- Ethmoidectomy that was unilateral or partial.
- Currently participating in an investigational drug or device study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/11/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/08/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
50
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Lyra Investigational Site - Bedford Park
Query!
Recruitment hospital [2]
0
0
Lyra Investigational Site - Brisbane
Query!
Recruitment hospital [3]
0
0
Lyra Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [2]
0
0
- Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kentucky
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Louisiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Utah
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Washington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Lyra Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220
designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior
functional endoscopic sinus surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05035654
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05035654
Download to PDF